You have a lot to protect, bank more than cord blood.

What is Regenerative Medicine?

Definition: Regenerative medicine is the science of repairing or replacing tissues and organs that have been damaged by congenital defects, disease, trauma, or aging, and restoring their normal functions.1

It is estimated that regenerative medicine could benefit millions of Americans with chronic and/or debilitating ailments. And the day when these patients begin to benefit may not be far off. In fact, the US Department of Health and Human Services expects regenerative medicine to make significant advances over the next 10 to 20 years.2

By stimulating the repair of organs that were thought to be permanently damaged, regenerative medicine may revolutionize health care, providing effective therapies for previously untreatable diseases and conditions.

Imagine what this potential may mean to a child born today!

Stem cell therapy is being studied for use in the following diseases†,2-10
Cerebral palsy* Parkinson's disease
Type 1 diabetes Spinal cord injury
Liver disease Traumatic brain injury
Heart disease Muscular dystrophy
Ophthalmic diseases Orthopedic injury
Hearing loss Stroke
* LifebankUSA has released stem cells for clinical study of this disease.

New potential for type 1 diabetes

Type 1 diabetes (also called juvenile onset diabetes) is a disorder of the immune system which, under normal circumstances, protects the body from viruses, bacteria, and foreign supstances.

Researchers at the University of Florida studied young children (aged 2 to 7 years) with type 1 diabetes, each of whom had cord blood banked at birth. The children received transplants using their own stem cells. Results for the first 6 months post transplant showed that the children's blood sugar levels were better controlled, and they required lower insulin doses each day. The stem cells also positively affected their immune systems.12

A significant improvement in cerebral palsy

Cerebral palsy impacts muscle control and coordination often causing severe developmental delays in movement and speech. The condition is caused by damage to certain parts of the brain during the prenatal period, the birth process, or in infancy-although the cause of this condition is usually unknown.

Treating cerebral palsy with cord blood stem cells may repair the injured parts of the brain by replacing damaged cells with healthy ones. In fact, disease improvement has been observed in 30 patients in a recent study at Duke University Medical Center.13

† These uses are not consistent with the current labeling.
Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400.† These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client's overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA ( 1-877-543-3226 ).

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.
† Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.

References:
  1. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
  2. US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. http://archive.hhs.gov/drugs/. Accessed Nov 14, 2011.
  3. Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4(4):269-274.
  4. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke. 2007;38(suppl 2):817-826.
  5. Jazedje T, Secco M, Vieira NM, et al. Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro. J Transl Med. 2009;7:6.
  6. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
  7. Shyu MK, Yuan RH, Shih JC, et al. Kinetics and functional assay of liver repopulation after human cord blood transplantation. Dig Liver Dis. 2007;39(5);455-456.
  8. Revoltella RP, Papini S, Rosellini A, et al. Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. Cell Transplant. 2008;17(6):665-678.
  9. Harris DT, Badowski M, Ahmad N, Gaballa MA. The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther. 2007;7(9):1311-1322.
  10. Dasari VR, Spomar DG, Li L, Gujrati M, Rao JS, Dinh DH. Umbilical cord blood stem cell mediated downregulation of Fas improves functional recovery of rats after spinal cord injury. Neurochem Res. 2008;33(1):134-149.
  11. Haller MJ, Viener H-L, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36(6):710-715.
  12. Haller MJ, Wasserfall CH, McGrail KM, et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care. 2009;32(11):2041-2046.
  13. Clinical Trials; A service of the U.S. National Institute of Health.